Federal Supreme Court upholds its stricter Pfizer case law
In its last week's published decisions (2C_145/2018, 2C_147/2018), the Federal Supreme Court upheld its stricter case law on the permissibility of price recommendations and vertical price agreements thereby confirming its Pfizer practice (Lenz & Staehelin Update Newsflash, Kluwer Competition Law Blog).
Marcel Meinhardt and his team represent Pfizer before the Competition authorities.